Individual and Combined Endothelin Receptor and SGLT1/2 Antagonism in Adults With Type 1 Diabetes Mellitus and Chronic Kidney Disease: a Phase 2, Multicenter, Open-label Randomized Cross-over Trial

The aim of this study is to test the hypothesis that sotagliflozin (SGLT1/2 inhibitor) and ambrisentan (ERA) combination therapy augments nephroprotection and mitigates fluid retention and ketogenesis in people with T1D through complementary and synergistic mechanisms of actions.

开始日期2024-03-01

申办/合作机构

University Medical Center Groningen

[+2]

NCT06256432 / Recruiting临床2期

A Multi-Centre, Randomised, Open-Label, Phase II Study of Ambrisentan in Patients With Hepatorenal Syndrome

Patients with advanced cirrhosis of the liver develop kidney problems occasionally. This condition is called Hepatorenal Syndrome, requires hospitalization and frequently results in death.
The goal of this clinical trial is to test whether the administration of low doses of ambrisentan can help patients with Hepatorenal Syndrome and to determine if it is safe. Ambrisentan is a drug that is approved for the treatment of high blood pressure in the lungs at higher doses.
This clinical trial will compare the safety and effects of ambrisentan to another drug called terlipressin, which is commonly used to treat patients with hepatorenal syndrome.
The main questions the clinical trial aims to answer are:
Does ambrisentan help the kidney function of the patient?
Does ambrisentan help prevent death in patients with Hepatorenal Syndrome?
Does ambrisentan prevent Hepatorenal Syndrome from reappearing?
While in the hospital, trial participants will receive either one of two doses of ambrisentan or terlipressin. If in the first 4 days, ambrisentan is not helpful, the patient may be eligible to receive terlipressin. Patients assigned to receive ambrisentan will continue taking this medication at home after leaving the hospitals and until they complete 60 days of treatment.

开始日期2024-03-01

申办/合作机构

Noorik Biopharmaceuticals AG

CTRI/2024/01/061915 / Not yet recruiting临床2期

A Multi-Centre, Randomised, Open-Label, Phase II Study of Ambrisentan in Patients with Hepatorenal Syndrome - NIL

开始日期2024-02-20

申办/合作机构

Noorik Biopharmaceuticals AG

100 项与安立生坦相关的临床结果

登录后查看更多信息

100 项与安立生坦相关的转化医学

登录后查看更多信息

100 项与安立生坦相关的专利（医药）

登录后查看更多信息

423

项与安立生坦相关的文献（医药）

2024-02-20·Internal and emergency medicine

Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.

Article

作者: Mustafa Erdogan ; Sinem Nihal Esatoglu ; Burcak Kilickiran Avci ; Gulen Hatemi

The evidence for the treatment of connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) mostly depends on subgroup or post hoc analysis of randomized controlled trials (RCTs). Thus, we performed a meta-analysis of RCTs that reported outcomes for CTD-PAH. PubMed and EMBASE were searched for CTD-PAH treatment. The selected outcomes were functional class (FC) change, survival rates, 6-min walk distance (6-MWD), clinical worsening (CW), N-terminal prohormone BNP (NT-proBNP), pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (mPAP), right atrial pressure (RAP), and cardiac index (CI). The meta-analysis was conducted according to the PRISMA guidelines and registered in PROSPERO (CRD42020153560). Twelve RCTs conducted with 1837 patients were included. The diagnoses were systemic sclerosis in 59%, SLE in 20%, and other CTDs in 21%. The pharmacological interventions were epoprostenol, treprostinil, sildenafil, tadalafil, bosentan, macitentan, ambrisentan, riociguat, and selexipag. There was a significant difference between interventions and placebo in FC, 6MWD, CW, PVR, RAP, and CI that favored intervention. Our analysis showed a 39% reduction in the CW risk with PAH treatment. The short-term survival rates and mean serum NT-proBNP changes were similar between the study and control groups. Treatment for CTD-PAH had favorable effects on clinical and hemodynamic outcomes but not on survival and NT-proBNP levels. Different from the previous meta-analyses that focused on 6-MWD, time to clinical worsening, and CW as outcomes, this meta-analysis additionally reports the pooled analysis of change in FC, hemodynamic measurements (RAP, PVR, CI), and NT-proBNP, some of which have prognostic value for PAH.

2024-02-20·Clinical pharmacology and therapeutics

How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians.

Article

作者: Ameet Sarpatwari ; Zhigang Lu ; Massimiliano Russo ; Heidi Zakoul ; Su Been Lee ; Gita A Toyserkani ; Esther H Zhou ; Cynthia LaCivita ; Katherine Hyatt Hawkins Shaw ; Laura Zendel ; Gerald J Dal Pan ; Aaron S Kesselheim

The US Food and Drug Administration can require risk evaluation and mitigation strategy (REMS) programs for prescription drugs to ensure the benefits of use outweigh the risks. We conducted a national survey of physicians' experiences prescribing eight REMS-covered drugs: (1) ambrisentan; (2) bosentan; (3) clozapine; (4) isotretinoin; (5-7) the multiple myeloma (MM) drugs lenalidomide, pomalidomide, thalidomide; and (8) sodium oxybate. Between May 2022 and January 2023, we surveyed 5,331 physician prescribers of these drugs, and 1,295 (24%) returned surveys (range: 149 for bosentan to 226 for MM drugs). Although 765 (68%) respondents thought the certification process provided useful drug information, 757 (67%) wanted materials to include benefit data and 944 (84%) non-REMS-related risk data. A majority (704, 63%) thought the safe use requirements facilitated discussion with patients, but a similar number (637, 57%) attributed delayed medication access to these requirements. In multivariable modeling, MM drug and isotretinoin respondents were less likely than sodium oxybate respondents to agree that the certification process provided useful drug information (MM drug: odds ratio (OR) = 0.37, 95% confidence interval (CI) = 0.25-0.55; isotretinoin: OR = 0.39, 95% CI = 0.25-0.61), and isotretinoin, clozapine, and bosetan respondents were more likely than sodium oxybate respondents to agree that the safe use requirements often delayed medication access (isotretinoin: OR = 5.83, 95% CI = 3.70-9.19; clozapine: OR = 1.65, 95% CI = 1.08-2.54; bosentan: OR = 1.78, 95% CI = 1.12-2.85). Most physicians believe REMS programs convey useful drug safety information and facilitate discussion with patients but also seek information on benefits and non-REMS-related risks and better integration of REMS processes into clinical workflows.

2024-02-16·European journal of pediatrics

Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.

Article

作者: Dunbar Ivy ; Maurice Beghetti ; Ernesto Juaneda-Simian ; Ramiya Ravindranath ; Mary Ann Lukas ; Sandra Machlitt-Northen ; Nicola Scott ; Jun Narita ; Rolf M F Berger

This open-label, extension study assessed long-term safety, tolerability, and efficacy of ambrisentan in a pediatric population (age 8- < 18 years) with pulmonary arterial hypertension (PAH). Following completion of a 6-month, randomized study, participants entered the long-term extension at individualized ambrisentan dosages (2.5/5/7.5 or 10 mg/day). Safety assessments included adverse events (AEs), AEs of special interest, and serious AEs (SAEs); efficacy outcomes included 6-min walking distance (6MWD) and World Health Organization functional class (WHO FC). Thirty-eight of 41 (93%) randomized study participants entered the extension; 21 (55%) completed (reaching age 18 years). Most participants received concomitant phosphodiesterase-5 inhibitors (n = 25/38, 66%). Median ambrisentan exposure was 3.5 years. Most participants experienced ≥ 1 AE (n = 34/38, 89%), and 21 (55%) experienced SAEs, most commonly worsening PAH (n = 3/38, 8%), acute cardiac failure, pneumonia, or anemia (n = 2/38; 5% each); none considered ambrisentan-related. Seven participants (18%) died, with recorded reasons (MedDRA preferred term): cardiac failure (n = 2), PAH (n = 2), COVID-19 (n = 1), acute right ventricular failure (n = 1), and failure to thrive (n = 1); median time to death: 5.2 years. Anemia and hepatotoxicity AEs were generally mild to moderate and did not require ambrisentan dose adjustment. Assessed at study end in 29 participants (76%), mean 6MWD improved by 17% (standard deviation: 34.3%), and all (29/29, 100%) had improved or unchanged WHO FC. Conclusion: Long-term weight-based ambrisentan dosing, alone or combined with other PAH therapies in children with PAH aged 8- < 18 years, exhibited tolerability and clinical improvements consistent with prior randomized study results. Trial registration: NCT01342952, April 27, 2011. What is Known: • The endothelin receptor antagonist, ambrisentan, is indicated for treatment of pulmonary arterial hypertension (PAH). Previous studies have shown similar efficacy and tolerability in pediatric patients as in adults. What is New: • This open-label extension study assessed the long-term use of ambrisentan in pediatric patients (8-<18 years) with PAH, most of whom were also receiving recommended background PAH treatment. • Weight-based dosing of ambrisentan, given alone or in combination with other PAH therapies, was well tolerated with clinical improvements consistent with prior randomized study results.

项与安立生坦相关的新闻（医药）

2024-04-06

·药渡

本土Biotech与MNC合作进入2.0时代：汇总分析３起医药并购案例

来源：药渡撰文：书本滑编辑：哦呼2023年末以来，国内biotech交易合作市场出现了一个新的现象，就是国外医药企业并购本土biotech，而且至今已经发生了3起相关并购交易。其中两起为MNC并购国内biotech。01阿斯利康并购亘喜生物2023年12月26日，阿斯利康宣布对亘喜生物科技集团（纳斯达克股票代码：GRCL；简称“亘喜生物”）的收购提案签署最终协议，从而完成对中国本土biotech亘喜生物的收购。亘喜生物是一家处于临床阶段的生物制药公司，致力于开发治疗肿瘤及自身免疫性疾病的创新性细胞疗法，核心品种为GC012F CAR-T细胞疗法。基于FasTCAR技术平台打造的GC012F是一款处于临床阶段的创新型BCMA/CD19双靶点自体嵌合抗原受体T细胞疗法（CAR-T)，有望成为针对多发性骨髓瘤、其他多类恶性血液肿瘤以及自身免疫性疾病（包括系统性红斑狼疮——SLE）的新一代治疗方案。根据最终协议条款，阿斯利康将合并收购亘喜生物的所有稀释后股份（包括所有ADS代表的股份）。阿斯利康将在交易交割时，以普通股每股现金价格2.00美元（相当于每股ADS10.00美元）完成收购。此外，条款中还附加了一项不可交易的或有价值权益，阿斯利康将在达到特定监管相关里程碑时，支付普通股每股现金价格0.3美元（相当每股ADS 1.5美元)。交易对价中的现金首付部分的交易价值约为10亿美元，较之亘喜生物在2023年12月22日的收盘价溢价62%，另外如果这笔首付款以及潜在的或有价值付款达成的话，合计交易价值约为12亿美元。该项交易最终于2024年2月完成交割。亘喜生物拥有3个有关CAR-T的技术平台：FasTCAR平台TruUCAR平台SMART CART亘喜生物于2017年推出FasTCAR技术平台，顾名思义可加速细胞生产周期的时间，传统的CAR-T细胞生产周期需2-4周时间，很多患者在这段时间死亡，FasTCAR据称可次日完成，大幅缩短患者等待期，更快的惠及病人，降低疾病进展风险。FasTCAR将传统的“激活-转到-扩增”三个步骤缩减为“同步激活-转到”一步完成，另外省去体外扩增，直接体内扩增，节省大量时间。TruUCAR平台为同种异体CAR-T技术平台，区别于自体CAR-T，可以产生通用型产品。SMART CAR-T致力于治疗实体瘤。图1.公司Pipeline（来源：公司官网）02诺华收购信瑞诺２０２４年１月５日，诺华宣布就收购信瑞诺医药达成协议。信瑞诺医药是一家专注于肾脏疾病治疗领域的临床阶段的中国生物技术公司，成立于２０２１年，由Chinook Therapeutics与创始投资机构Pivotal bioVenture Partners China（鼎丰生科资本），Frazier Life Sciences，Samsara BioCapital和Versant Venture共同发起设立，是典型的由资本和技术共同发起设立的Bｉｏｔｅｃｈ。诺华于２０２３年８月，完成对Chinook的收购，从而间接持有信瑞诺部分股权，此次收购诺华将收购信瑞诺其余股份，交易完成后，信瑞诺将整体整合入诺华中国。信瑞诺目前拥有２款核心资产，开发适应症均为ＩｇＡ肾病：AtrasentanBION-1301Atrasentan为内皮素受体拮抗剂，内皮素受体拮抗剂并非新的机制靶点，已有多款药物上市，用于治疗肺动脉高血压，可以说是肺动脉高血压最常用一类药物，比如波生坦、安立生坦、马昔腾坦等。另外２０２４年３月１４日，FDA批准了内皮素受体拮抗剂Tryvio（Aprocitentan）用于治疗难治性高血压。内皮素用于IｇA肾病目前未有品种批准，Atrasentan为研发进度最快的品种，处于III期临床阶段，有望２０２４年通过加速批准路径获得FDA批准。国内企业信立泰有一款内皮素受体拮抗剂SAL0120，用于IｇA肾病，处于I期临床阶段。BION-1301是一种皮下给药的抗APRIL单克隆抗体。03Nuvation Bio收购葆元医药２０２４年３月２５日，Nuvation Bio Inc.（纽约证券交易所股票代码：NUVB）和葆元生物医药宣布，Nuvation Bio以全股票交易方式收购葆元。收购交割后，葆元的前股东将持有Nuvation Bio 33%的股份，而Nuvation Bio的现有股东将持有Nuvation Bio约67%的股份。交易预计于２０２４年第二季度交割完成。葆元医药成立于２０１８年，是一家开发新型肿瘤疗法的临床阶段生物制药公司，主要通过＂Ｌｉｃｅｎｓｅ－ｉｎ＂的业务模式，与日韩等境外主体达成合作而将药物商业化。葆元医药目前有３款核心资产：TaletrectinibSafusidenibAB－３２９Taletrectinib（泰莱替尼）是新一代ROS１高选择性、强效酪氨酸激酶抑制剂。最初由第一三共开发，葆元医药于２０１８年１２月获得全球独家权益，于２０２０年将韩国开发和商业化权益授予韩国公司NｅｗG Lab，于２０２１年与信达生物达成合作，信达生物获得与葆元医药在大中华区共同开发和商业化权益。泰莱替尼用于经ROS1-TKI治疗失败的ROS1阳性局部晚期或转移性非小细胞肺癌成人患者的治疗，上市申请已获NMPA受理。图2.（来源：公司官网）Safusidenib为IDH１选择性抑制剂，最初由第一三共开发，葆元医药获得除日本以外全球市场的开发权利，胶质瘤适应症开发处于临床II期。目前全球已经批准了3款IDH抑制剂上市，均针对AML。Enasidenib，于２０１７年获得FDA批准，为IDH２抑制剂，由Agios开发。Ivosidenib（艾伏尼布），２０１７年７月获得FDA批准，由Agios开发，为首款上市的IDH１抑制剂，2022年2月获的NMPA批准。Olutasidenib，于２０２２年１２月由FDA批准，由Rige开发，为IDH１抑制剂。AB－３２９为AXL抑制剂，拟开发适应症为与PD－１联用用于NSCLC，目前处于早期开发阶段。SUMMARY总结医药企业的核心是品种和技术平台，MNC对国内biotech的品种认可早已确定无疑，看重一个品种，多是以权益转让的方式，对于MNC与国内biotech的BD合作也已司空见惯。但是股权并购相对权益是更深度紧密的合作方式，当MNC更认可biotech的portfolio或者技术平台的时候，更倾向于采用并购的方式。但是，另外从biotech角度讲，当MNC特别看重一个品种的时候，如果biotech想被收购，为了得到该单个品种，可能也会收购。比如亘喜生物的CAR－T技术平台的布局（通用CAR－T、实体瘤CAR-T），可以说全覆盖了CAR－Ｔ领域，这对近年重金布局CAR－T疗法的阿斯利康来说极具吸引力。另外诺华并购信瑞诺是因为后者在IgA领域的研发领先优势，诺华也是看重肾病领域，不断加强布局。从行业生态维度，本土biotech与MNC的BD合作已经非常活跃，并购交易的不断增多有助于完善行业生态，并购是医药行业非常重要的一环，对于biotech的早期投资机构增加了退出渠道，biotech的出路除成长ｂｉｏpharma、权益转让之外，又多了一条并购路径。END*声明：本文仅是介绍医药疾病领域研究进展或简述研究概况或分享医药相关讯息，并非也不会进行治疗或诊断方案推荐，也不对相关投资构成任何建议。内容如有疏漏，欢迎沟通指出！【药企裁员风波不断】三月汇总Wegovy日本热卖，诺和诺德为何将亚洲首站设在此地？FDA九个月内批准的三种DMD治疗方法点击蓝字 | 关注我们

细胞疗法并购免疫疗法

2024-03-03

·蒲公英Ouryao

“大字版”药品说明书或将搭配语音播报功能

转自：人民日报健康客户端（有删减）“药品说明书上的字变大了！不戴老花镜也能看清了。”据光明网2月29日报道，浙江首批“大字版”药品说明书上线，华海药业生产的抗高血压药安立生坦片药品说明书从8200多字降为1400多字，字号也从小五号增大为四号。为改变“一粒米盖住四个字”的药品说明书窘境，国家药监局于2023年12月26日公布了包括华润双鹤药业的普瑞巴林胶囊等657种药品说明书适老化及无障碍改革试点名单（第一批）。 3月2日，人民日报健康客户端记者从华润双鹤药业股份有限公司获悉，华润双鹤目前已开发电子说明书微信小程序，制定了说明书适老化项目实施方案。首个试点品种普瑞巴林胶囊已向提交北京市药品监督管理局进行说明书备案，预计于2024年二季度上市。根据国家药监局公布的《药品说明书适老化及无障碍改革试点工作方案》，按照省级药品监管部门组织、药品上市许可持有人自愿申请、分步实施的原则，确定上海、江苏、浙江、江西、山东、湖南、广东、陕西等省（市）为试点省份。其他省市持有人有参与试点工作意向的，可以向所在地省级药品监管部门提出申请，省级药品监管部门审核后报国家药监局。华润双鹤相关负责人告诉人民日报健康客户端记者，华润双鹤将采取简化版纸质药品说明书和完整版电子药品说明书，同时增加语音播报音频。上述负责人介绍，这意味着每个销售单元按要求配备纸质简化版药品说明书，将二维码印刷在说明书上。扫描纸质说明书上二维码后，就可以获得电子完整版药品说明书及说明书部分内容的语音播报音频。2023年总结类文章推荐:推荐阅读：蒲公英Ouryao视频号投稿、广告、商务合作： Qinrenlvcha

2023-11-08

·米内网

【瞩目】石四药1类新药来袭！4大“光脚”品种拟中选第九批集采

精彩内容近日，石四药动态频频：11月8日，其申报的化学药SYN045片的临床申请获得CDE承办受理，为今年首款申报的1类新药；11月7日，石四药公告称，在第九批国采中，公司有4个新产品拟中选。据公司公告，SYN045片是一款抗肺动脉高压药物，具体作用机制暂未披露。肺动脉高压是由多种因素引起的肺动脉阻力进行性增高、肺血管重塑、右室肥厚，并最终引起右心衰竭甚至死亡的一种恶性心血管疾病，致死率跟癌症类似，也被称为心血管领域的“癌症”。米内网数据显示，目前国内获批的专用于肺动脉高压的药物主要有马昔腾坦、安立生坦、利奥西呱、波生坦等。虽然已获批的药物数量并不多，但近年来其相应的用药市场在中国三大终端六大市场（统计范围详见本文末）均以两位数的增速扩容，2022年超过4亿元，同比增长约36%。在创新药领域，石四药已有1款抗肿瘤1类新药——NP-01片在开展I期临床，这是一款适度选择性的KDR/MET/Axl多靶点激酶抑制剂，可以实现对肿瘤新生血管的控制，调控肿瘤微环境，激活自身免疫系统，提高肿瘤治疗效果。此外，治疗肝纤维化的1类新药ADN-9目前已完成了I期临床申报前与CDE的沟通交流，力争2023年下半年开始I期临床试验。NP-01片临床进展来源：米内网中国临床试验数据库11月6日，第九批集采如期开标，石四药共有4个新产品（3个为2023年获批）拟中选：阿奇霉素干混悬剂（0.1g）、盐酸乌拉地尔注射液（5ml:25mg）、注射用磷酸特地唑胺（200mg）均以第一顺位中选，胞磷胆碱钠注射液（4ml:0.5g）以第九顺位中选。与最高有效申报价比，上述4个产品降幅分别达84.56%、84.25%、81.65%、62.32%。石四药第九批集采拟中选情况来源：公司公告等从供应省区看，阿奇霉素干混悬剂（0.1g）将独家供应浙江、广东、云南、吉林和河北共5个省，盐酸乌拉地尔注射液（5ml:25mg）将独家供应浙江、山东、安徽和云南共4个省，注射用磷酸特地唑胺（200mg）将独家供应河北、江苏、浙江、广西和海南共5个省，胞磷胆碱钠注射液（4ml:0.5g）将独家供应云南、浙江和青海共3个省。石四药预期，此次中标将有利于相关新产品迅速开发市场，形成规模销售，提高市场占有率，对集团未来销售带来正面的影响。资料来源：米内网数据库、公司公告等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至11月8日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

申请上市临床1期临床申请

100 项与安立生坦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07077	安立生坦	C02KX02	DB06403

研发状态

适应症	最高研发状态	国家/地区	公司
肺动脉高压	批准上市	欧盟更多	MyLan SAS 更多
肺性高血压	临床3期	阿根廷更多	Gilead Sciences, Inc. 更多
缺氧	临床2期	西班牙更多	Noorik Biopharmaceuticals AG 更多
新型冠状病毒感染	临床2期	西班牙更多	Noorik Biopharmaceuticals AG 更多
高血压	终止	韩国更多	GSK Plc 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00617305 (ATHENA-1, Pubmed \| Respir Med) 人工标引	临床4期	肺动脉高压	33	PDE5i+ambrisentan	(廠艱鬱選壓夢遞鏇構壓) = 鹹憲顧選鑰積鑰築衊製鬱醖膚襯醖餘蓋艱網網 (觸網蓋製鹽願窪夢鬱構 ) 更多	积极	2017-05-01
NCT01042158 (Pubmed \| Pediatrics) 人工标引	临床4期	肺动脉高压	24	Ambrisentan+Tadalafil	鹹繭鏇獵壓積獵願廠淵(鹽膚淵製鏇廠觸淵糧醖) = 選淵遞齋夢鑰淵範憲構衊網簾廠顧襯鹽淵觸構 (遞繭淵憲夢繭廠餘鹹糧, 4.0 ~ 12.9) 更多	积极	2015-11-01
NCT01072669 (Pubmed \| J Rheumatol) 人工标引	N/A	系统性硬皮病	20	ambrisentan	蓋鹽鑰餘築鑰選膚遞製(築鏇醖範艱選鏇鹽構願) = We conclude that continuous use of ambrisentan for three months does not seem to significantly improve digital blood flow in SSc patients. 窪顧壓夢選繭選積繭夢 (獵製壓範鬱獵夢夢艱壓 ) 更多	不佳	2015-03-05
NCT01072669 (Pubmed \| J Rheumatol) 人工标引	N/A	系统性硬皮病	20	Placebo		不佳	2015-03-05
NCT02290613 (EDITA, Pubmed \| J Rheumatol) 人工标引	临床2期	系统性硬皮病	38	ambrisentan	廠鏇築遞廠膚願壓築獵(積繭淵醖廠顧積艱鹹願) = 餘網夢範鹹窪顧膚獵醖獵鹹構憲積鑰鹽醖醖鏇 (遞餘遞繭鹹壓憲鑰衊憲, 6.4) 更多	积极	2019-10-26
NCT02290613 (EDITA, Pubmed \| J Rheumatol) 人工标引	临床2期	系统性硬皮病	38	Placebo	廠鏇築遞廠膚願壓築獵(積繭淵醖廠顧積艱鹹願) = 憲網膚鬱鹽膚鬱簾製壓獵鹹構憲積鑰鹽醖醖鏇 (遞餘遞繭鹹壓憲鑰衊憲, 3.59) 更多	积极	2019-10-26
NCT01224210 (Portopulm, Pubmed \| J Heart Lung Transplant) 人工标引	临床3期	高血压	23	Ambrisentan	(齋獵衊齋顧網選餘範遞) = 314 ± 94 vs 336 ± 108 m 夢壓艱獵廠鏇壓壓醖憲 (製製簾遞簾鹽獵廠遞鬱 ) 更多	积极	2020-05-01
NCT01808313 (Pubmed \| BMC Cardiovasc Disord) 人工标引	临床3期	肺动脉高压	133	Ambrisentan	(觸簾繭衊壓構糧顧鑰製) = 膚願淵網選齋蓋簾壓蓋構製鹹鹹憲糧範襯衊夢 (襯築餘鏇壓積壓鑰願窪 ) 更多	积极	2016-10-22
NCT01093885 (Pubmed) 人工标引	N/A	弥漫性硬皮病	10	antifibrotic agent+ambrisentan	艱顧鏇蓋膚蓋鏇築憲餘(願製顧淵鏇鹽鹹範觸鹽) = 蓋選獵簾衊襯壓憲艱簾蓋鬱蓋鹹窪鹽齋壓鑰鏇 (遞憲網顧願壓糧製襯膚, 11.2) 更多	积极	2018-05-15
NCT01338636 (Pubmed \| Pulm Circ) 人工标引	临床4期	肺性高血压	30	ambrisentan	觸鏇簾網顧鹹鹹艱窪製(衊艱積艱壓憲鏇窪遞鏇) = 鹹繭憲齋鬱築選廠鏇選夢壓膚繭願壓繭繭構鹽 (憲醖鏇願膚觸窪願獵憲, 1.4) 更多	积极	2017-04-01
NCT05437224 (Pubmed)	临床3期	肺动脉高压	83	Ambrisentan	(蓋顧淵窪鏇構範膚網醖) = 壓願製範艱襯餘鏇築憲繭範積網窪選襯構夢襯 (鑰憲鏇鏇齋夢願艱壓膚 ) 更多	-	2023-01-01
NCT01884675 (AMBER I, Pubmed \| Pulm Circ) 人工标引	临床3期	慢性血栓栓塞性肺动脉高压	28	Ambrisentan	(築繭積膚遞顧觸積繭餘) = adverse event profiles were similar between groups. 遞鹹選鏇壓糧齋鬱淵蓋 (憲夢鑰觸構鬱襯壓鏇襯 ) 更多	积极	2019-04-01
NCT01884675 (AMBER I, Pubmed \| Pulm Circ) 人工标引	临床3期	慢性血栓栓塞性肺动脉高压	28	Placebo		积极	2019-04-01